Back

SGLT2 inhibitors on the prevention of contrast-induced acute kidney injury in patients with type 2 diabetes after coronary revascularization: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (3) - Pharmacotherapy Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Kyriakos Dimitriadis

Hippokration General Hospital, Athens (Greece)

8 More presentations in this session

Presentation thumbnail
Discussant - Pharmacotherapy
Presentation thumbnail
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Ph2 Trial of Pacibekitug SC Quarterly or Monthly in Patients with Elevated hs-CRP and Chronic Kidney Disease: TRANQUILITY 90-Day Results
Professor D. Bhatt (New York City, US)
Presentation thumbnail
Comparative effectiveness of angiotensin ii receptor blockers versus angiotensin-converting enzyme inhibitors in acute myocardial infarction
Doctor P. Sun (Tianjin, CN)
Abstract Video
Presentation thumbnail
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Video
Presentation thumbnail
Comparative effectiveness of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis with intervention ranking
Doctor M. Rahman (Flushing, US)
Abstract Video

Access the full session

Session thumbnail
New perspectives in cardiology (3) - Pharmacotherapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Young Investigator Award Session in Interventional Cardiology
thumbnail
Congress Presentation
Rethinking acute kidney injury risk: beyond contrast volume in acute myocardial infarction
thumbnail
Congress Presentation
SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources